Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,820,594
  • Shares Outstanding, K 208,306
  • Annual Sales, $ 7,410 K
  • Annual Income, $ -166,410 K
  • 60-Month Beta 0.76
  • Price/Sales 253.25
  • Price/Cash Flow N/A
  • Price/Book 3.58
Trade INO with:

Options Overview

Details
  • Implied Volatility 101.57%
  • Historical Volatility 55.36%
  • IV Percentile 4%
  • IV Rank 6.15%
  • IV High 279.67% on 06/25/20
  • IV Low 89.90% on 03/30/21
  • Put/Call Vol Ratio 0.22
  • Today's Volume 36,699
  • Volume Avg (30-Day) 22,969
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 265,339
  • Open Int (30-Day) 192,084

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.21
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.06 +8.44%
on 04/12/21
10.56 -17.23%
on 03/17/21
-1.73 (-16.52%)
since 03/16/21
3-Month
8.06 +8.44%
on 04/12/21
19.00 -54.00%
on 02/02/21
-0.92 (-9.52%)
since 01/15/21
52-Week
7.54 +15.92%
on 04/17/20
33.79 -74.13%
on 06/26/20
+0.85 (+10.77%)
since 04/16/20

Most Recent Stories

More News
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)

Inovio Pharmaceuticals, Inc. (NasdaqGS: INO)

INO : 8.74 (-3.00%)
MMSI : 61.78 (+0.68%)
RICK : 66.64 (-2.89%)
VNDA : 16.67 (-0.66%)
Interesting INO Put And Call Options For November 19th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the November 19th expiration.

INO : 8.74 (-3.00%)
Thinking about buying stock in Inovio Pharmaceuticals, AMC Entertainment, Citigroup, Syros Pharmaceuticals, or Avinger?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INO, AMC, C, SYRS, and AVGR.

AC : 33.12 (-3.27%)
AVGR : 1.1400 (-5.79%)
INO : 8.74 (-3.00%)
SYRS : 6.22 (-4.45%)
AMC : 9.33 (-5.76%)
C : 72.45 (-0.12%)
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer,...

INO : 8.74 (-3.00%)
Do Options Traders Know Something About Inovio (INO) Stock We Don't?

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

INO : 8.74 (-3.00%)
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals...

INO : 8.74 (-3.00%)
INO May 28th Options Begin Trading

Investors in Inovio Pharmaceuticals Inc. saw new options become available today, for the May 28th expiration.

INO : 8.74 (-3.00%)
QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio

QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.

HOLX : 76.66 (+0.88%)
QGEN : 52.75 (+0.11%)
HRC : 114.56 (+0.46%)
INO : 8.74 (-3.00%)
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting...

ALPMF : 14.7610 (+0.41%)
CYCC : 6.52 (-4.40%)
GSK : 37.75 (+0.16%)
INO : 8.74 (-3.00%)
PBYI : 10.07 (-1.37%)
TYME : 1.5300 (+0.66%)
Human Papillomavirus Protein E7 Market Analysis, Recent Trends, Development, Top Company Players and Forecast 2020-2027 by Ameco Research

pune, India, Tue, 30 Mar 2021 02:52:43 / Comserve Inc. / -- Ameco Research indicates that the Global Human Papillomavirus Protein E7 Market is expected to surge at a steady rate in the coming years, as...

ADXS : 0.4690 (-9.67%)
IBIO : 1.2300 (-4.65%)
IMV.TO : 3.47 (-1.98%)
INO : 8.74 (-3.00%)
MFAC : 14.76 (-0.74%)
SELB : 3.87 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 9.40
2nd Resistance Point 9.19
1st Resistance Point 8.96
Last Price 8.74
1st Support Level 8.52
2nd Support Level 8.31
3rd Support Level 8.08

See More

52-Week High 33.79
Fibonacci 61.8% 23.76
Fibonacci 50% 20.67
Fibonacci 38.2% 17.57
Last Price 8.74
52-Week Low 7.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar